HRT for perimenopause: a plain-English guide to hormone therapy

HRT (hormone replacement therapy), now often called MHT (menopausal hormone therapy), replaces the estrogen your ovaries are producing less of, and adds progesterone if you still have a uterus (to protect the uterine lining). It's the single most effective treatment for hot flashes, night sweats, and genitourinary symptoms, and it also supports sleep, mood, bone density, and — when started in the perimenopausal window — likely cardiovascular health.

For most healthy women starting in perimenopause or within 10 years of menopause and under age 60, modern HRT is considered safe and the benefits outweigh the risks. The 2002 Women's Health Initiative study that scared a generation used older oral estrogen plus a synthetic progestin in an average-age-63 population — the risks it flagged do not translate cleanly to today's transdermal estradiol plus micronized progesterone in a 45-year-old. Absolute risks are small; talk to a menopause-informed clinician about your personal history.

The main risks people discuss are venous thromboembolism (blood clots), stroke, and breast cancer. Transdermal estradiol (patch, gel, spray) does NOT appear to raise clot or stroke risk in most women, unlike oral estrogen. Breast cancer risk with combined estrogen + progestogen is small in absolute terms (roughly one extra case per 1,000 women per year of use after five years, less with micronized progesterone). Estrogen-only HRT (for women without a uterus) has not shown increased breast cancer risk in the WHI data. Contraindications include active or recent breast cancer, active clotting disorders, unexplained vaginal bleeding, and active liver disease.

You can, and often should, start in perimenopause. This is one of the most common misconceptions. HRT is not reserved for postmenopause — it can be started as soon as symptoms are disrupting your life, even while you're still cycling. If you still get periods, you'll typically be on cyclical progesterone (12 days a month) or a continuous low dose plus estrogen; postmenopause, progesterone is usually daily. If you're under 45, treatment is even more important because the estrogen deficiency happens sooner and lasts longer.

Patches, gels, and sprays deliver estradiol through the skin (transdermal), bypassing the liver. This route avoids the first-pass liver effect that raises clotting factors, so transdermal is preferred for most women, especially with any clotting-risk factors (migraine with aura, obesity, smoking history, family history of clots). Oral estradiol pills are equally effective for symptoms but carry a small extra clot risk. Vaginal estrogen (cream, ring, or tablet) is a separate, very-low-dose local treatment for genitourinary symptoms and is safe even for many women who can't take systemic HRT.

Micronized progesterone (brand name Prometrium in the US, Utrogestan in the UK) is bioidentical and preferred over older synthetic progestins like medroxyprogesterone acetate (MPA). It has a better safety profile for breast tissue in observational data, and it often helps sleep as a side benefit because it's mildly sedating (taken at night). Synthetic progestins are still prescribed but are usually the older WHI-era formulations. If you have a uterus, you MUST take a progestogen alongside estrogen — estrogen alone thickens the uterine lining and raises endometrial cancer risk.

Hot flashes and night sweats usually improve within 2 to 4 weeks and continue improving for 3 months. Sleep often improves in the first month. Mood and brain fog take longer — often 2 to 3 months. Genitourinary symptoms (vaginal dryness, painful sex, urinary urgency) can take 2 to 3 months with local vaginal estrogen. If you're not getting relief after 3 months at a standard dose, the dose or route may need to be adjusted. Don't quit at week 4 — most protocols require a full quarter to evaluate.

There's no hard stop. The old advice of 'lowest dose, shortest time' has been walked back by most major menopause societies (NAMS, IMS, British Menopause Society). Many women stay on HRT for 5 to 10 years, and some longer, especially if they started young. The decision is annual and personal — you and your clinician re-evaluate based on symptoms, benefits (bone, cardiovascular, quality of life), and any changes in risk profile. Coming off HRT is done by tapering, not stopping suddenly.

Unfortunately common — most primary care doctors received minimal menopause training. Options: (1) ask for a referral to a gynecologist or menopause specialist, (2) find a certified menopause practitioner through the Menopause Society's directory (menopause.org), (3) consider a telemedicine menopause clinic (Midi, Alloy, Evernow, and others in the US). Bring a symptom log, ask specifically about transdermal estradiol and micronized progesterone, and ask for the reasoning if you're refused — 'you're too young' or 'you're not menopausal yet' are not evidence-based reasons in 2026.

For vasomotor symptoms (hot flashes, night sweats), non-hormonal prescription options include fezolinetant (a newer NK3 antagonist targeting the KNDy neurons that drive hot flashes), low-dose SSRIs/SNRIs (paroxetine, venlafaxine, escitalopram), gabapentin, and clonidine. For sleep, CBT-I is first-line non-drug therapy. For mood, SSRIs and CBT are effective. For bone, bisphosphonates. For genitourinary symptoms, low-dose vaginal estrogen has a very different risk profile from systemic HRT and is often safe even for women who can't take systemic hormones. Lifestyle changes help but rarely replace HRT for moderate to severe symptoms.